Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 7% of the time (318 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2008-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: safety tolerabilityliverinvestigational ortolerability pharmacokineticsmonths
  Phrases that lowered it: healthysubjectprescriptionml ofasthma
• Sponsor's past termination rate: 3.4% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 546 (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Minimum age: 20 (lowers risk) · Who can join
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 641 (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Number of arms: not given (raises risk) · Design
• Blinding: double (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Maximum age: 64 (lowers risk) · Who can join
• Disease area, psychiatry: No (lowers risk) · Disease area
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848 NCT00743860 · started 2008 · scored riskier than 3% of active trials completed
• A Study With Darapladib to Collect Tolerability Information NCT00704431 · started 2008 · scored riskier than 3% of active trials completed
• Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers NCT02254109 · started 2008 · scored riskier than 7% of active trials completed
• A Clinical Trial to Compare the Pharmacokinetics and Safety of BR1016C With BR1016D in Healthy Volunteers NCT05102266 · started 2021 · scored riskier than 0% of active trials completed
• A Clinical Trial to Compare the Pharmacokinetics and Safety of BR1016A With BR1016B in Healthy Volunteers NCT05102903 · started 2021 · scored riskier than 0% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.